|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
����ø�� |
|
�źŴ��� |
|
Ƥ������ |
| ��������������� | |
|
����� |
|
������ |
|
֣�� |
| PubMed | |
|
Article by ����� |
|
Article by ������ |
|
Article by ֣�� |
ϸ���źŴ���������Ƥ������
�����1, ������2, ֣��1
1. �㽭��ѧҽѧԺ�����ڶ�ҽԺƤ���� ���� 310009;
2. �㽭��ѧҽѧԺ�����ڶ�ҽԺ����� ���� 310009
���Ŷ���������ѧ������ε��о�,�źŴ���;��������ϸ���п������ʹٽ��ֻ���ֳ������Խ��Խ�ܵ����ӡ�˿��ԭ����ĵ���ø���źŴ�����ת¼��������3��������Ҫ���źŴ���ͨ·�е���Ҫ�źż����ɷ�,����������������ϵ���о������ࡣ
1. �㽭��ѧҽѧԺ�����ڶ�ҽԺƤ���� ���� 310009;
2. �㽭��ѧҽѧԺ�����ڶ�ҽԺ����� ���� 310009
1. �㽭��ѧҽѧԺ�����ڶ�ҽԺƤ���� ���� 310009;
2. �㽭��ѧҽѧԺ�����ڶ�ҽԺ����� ���� 310009
�㽭ʡ���������л���(2004A046)
[2] Egan SE, Weinberg RA. The pathway to signal achievement. Nature,1993, 365:781-783.
[3] 0ka H, Chatani Y, Hoshino R, et al. Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma.Cancer Res, 1995, 55:4182-4187.
[4] Gioeli D, Mandell JW, Petroni GR, et al. Activation of mitogen-activated protein kinase associated with prostate cancer progression.Cancer Res, 1999, 59:279-284.
[5] Webb CP, Van Aelst L, Wiglet MH,et al. Signaling pathways in Rasmediated tumorigenicity and metastasis. Proc Natl Acad Sci USA,1998, 95:8773-8778.
[6] Molnar A, Theodoras AM, Zon LI,et al. Cdc42Hs, but not Racl, inhibits serum-stimulated cell cycle progression at GI/S through a mechanism requiring p38/RK. J Biol Chem, 1997, 272:13229-13235.
[7] Spector MS, Auer KL, Jarvis WD, et al. Differential regulation of the mitogen-activated protein and stress-activated protein kinase cascades by adrenergic agonists in quiescent and regenerating adult rat hepatocytes. Mol Cell Biol, 1997, 17:3556-3565.
[8] Ip YT, Davis RJ. Signal transduction by the c-Jun N-terminal kinase (JNK)-from inflammation to development. Curr Opin Cell Biol,1998, 10:205-219.
[9] Darnell JE Jr. STATs and gene regulation. Science, 1997, 277:1630.
[10] Niu G, Shain KH, Huang M,et al. Overexpression of a dominant-negative signal transducer and activator of transcription 3 variant in tumor cells leads to production of soluble factors that induce apoptosis and cell cycle arrest. Cancer Res, 2001, 61:3276-3280.
[11] Lin J, Jin X, Rothman K,et al. Modulation of signal transducer and activator of transcription 3 activities by p53 tumor suppressor in breast cancer cells. Cancer Res, 2002, 62:376-380.
[12] Kube D, Holtick U, Vockerodt M, et al. STAT3 is constitutively activated in Hodgkin cell lines. Blood, 2001, 98:762-770.
[13] Wang S, Evers BM. Caco-2 cell differentiation is associated with a decrease in stat protein levels and binding. J Gastrointest Surg, 1999,3:200-207.
[14] Berclaz G, Altermatt HJ, Rohrbach V, et al. EGFR dependent expression of STAT3 (but not STAT1) in breast cancer. Int J Oncol,2001, 19:1155-1160.
[15] Bowman T, Broome MA, Sinibaldi D, et al. Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. Proc Natl Acad Sci USA, 2001, 98:7319-7324.
[16] Budiyanto A, Bito T, Kunisada M, et al. Inhibition of the epidermal growth factor receptor suppresses telomerase activity in HSC-1 human cutaneous squamous cell carcinoma cells. J Invest Dermatol, 2003,121:1088-1094.
[17] Singh RP, Tyagi AK, Zhao J, et al. Silymarin inhibits growth and causes regression of established skin tumors in SENCAR nfice via modulation of mitogen-activated protein kinases and induction of apoptosis. Carcinogenesis, 2002, 23:499-510.
[18] Segrelles C, Ruiz S, Perez P, et al. Functional roles of Akt signaling in mouse skin tumorigenesis. Oncogene, 2002, 21:53-64.
[19] Zeliadt NA, Warmka JK, Wattenberg EV. Mitogen activated protein kinases selectively regulate palytoxin-stimulated gene expression in mouse keratinocytes. Toxicol Appl Pharmacol, 2003, 192:212.
[20] Katsanakis KD, Owen C, Zoumpourlis V. JNK and ERK signaling pathways in multistage mouse carcinogenesis: studies in the inhibition of signaling cascades as a means to understand their in vivo biological role. Anticancer Res, 2002, 22:755-759.
[21] She QB, Chen N, Bode AM, et al. Deficiency of c-Jun-NH(2)-terminal kinase-1 in mice enhances skin tumor development by 12-Otetradecanoylphorbol-13-acetate. Cancer Res, 2002, 62:1343.
[22] Zi X, Agarwal R. Modulation of mitogen-activated protein kinase activation and cell cycle regulators by the potent skin cancer preventive agent silymarin. Biochem Biophys Res Commun, 1999, 263:528.
[23] Hildesheim J, Bulavin DV, Anver MR,et al. Gadd45a protects against UV irradiation-induced skin tumors, and promotes apoptosis and stress signaling via MAPK and p53. Cancer Res, 2002, 62:7305.
[24] Eriksen KW, Kaltoft K, Mikkelsen G, et al. Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells. Leukemia, 2001, 15:787-793.
[25] Nielsen M, Kaestel CG, Eriksen KW, et al. Inhibition of constitutively activated Stat3 correlates with altered Bcl-2/Bax expression and induction of apoptosis in mycosis fungoides tumor cells. Leukemia,1999, 13:735-738.
[26] Brender C, Nielsen M, Kaltoft K, et al. STAT3-mediated constitutive expression of SOCS-3 in cutaneous T-cell lymphoma. Blood,2001, 97:1056-1062.
[27] Kirkwood JM, Farkas DL, Chakraborty A, et al. Systemic interferonalpha (IFN-alpha) treatment leads to Stat3 inactivation in melanoma precursor lesions. Mol Med, 1999, 5:11-20.
[28] Jee SH, Chiu HC, Tsai TF, et al. The phosphotidyl inositol 3-kinase/Akt signal pathway is involved in interleukin-6-nediated Mcl-1 upregulation and anti-apoptosis activity in basal cell carcinoma cells. J Invest Dermatol, 2002, 119:1121-1127.